Skip to content

Effect of Aerobic Exercise on Diurnal Cortisol Pattern in Premenstrual Syndrome

Effect of Aerobic Exercise on Diurnal Cortisol Pattern in Premenstrual Syndrome: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05507255
Enrollment
28
Registered
2022-08-18
Start date
2023-02-01
Completion date
2023-06-01
Last updated
2023-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual Syndrome

Keywords

Aerobic exercise, Relaxation training, Diurnal cortisol pattern, Premenstrual syndrome

Brief summary

The aim of this study will be to investigate the effect of aerobic exercise on diurnal cortisol pattern in premenstrual syndrome.

Detailed description

Premenstrual syndrome is manifested by recurrent emotional and depressive symptoms that may be associated with maladaptive coping with stress situations and the enhanced release of stress hormones, like cortisol hormone. Although previous studies revealed a flattened diurnal cortisol slope in women with PMS compared to healthy controls, there is no previous work on the effect of aerobic exercise on diurnal cortisol pattern in premenstrual syndrome. Therefore, this study will aim to investigate the effect of aerobic exercise participation on diurnal cortisol pattern in premenstrual syndrome.This trial will include two groups; group (A) will consist of 14 females who will receive relaxation training for 8 weeks, while group (B) will consist of 14 females who will receive the same relaxation training along with aerobic exercise for 8 weeks.

Interventions

OTHERRelaxation training

Relaxation training in the form of deep breathing exercises

OTHERAn aerobic exercise program

An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Random generator

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 23 Years
Healthy volunteers
No

Inclusion criteria

1. Sedentary, virginal, adult, non-smoker females suffering from premenstrual syndrome. 2. They should have regular menstrual cycles (cycles of 21-35 days with a bleeding time of 3-10 days) 3. They should have the following criteria in daily record of severity of problems in at least one of two consecutive menstrual cycles prior to treatment starting to confirm premenstrual syndrome diagnosis: a) more than three items have an average score over 3 during the luteal phase, and b) a luteal phase score is 30% more than a follicular phase score. 4. No traumatic life events in the last 2 months before starting the study. 5. Their age will be 18-23 years 6. Their body mass index (BMI) will be less than 30 kg/m2.

Exclusion criteria

1. Menstrual problems (e.g. menorrhagia, metrorhagia and polycystic ovary disease). 2. Cardio-respiratory, renal, neurological and pelvic inflammatory diseases, tumors, infections, anemia, diabetes, hypertension, asthma, rheumatoid arthritis, headache, migraine, thyroid or mental disorders. 3. Participation at any other exercise training program during this study. 4. Receiving any kind of medications, hormonal treatment or supplementation (vitamin, mineral or herbal supplement).

Design outcomes

Primary

MeasureTime frameDescription
Diurnal cortisol pattern8 weeksIt will be evaluated through calculating the ratio of morning cortisol level to evening cortisol level for all participants at baseline and after 8 weeks of treatment.
Severity of premenstrual symptoms8 weeksSeverity of premenstrual symptoms of all participants will be measured through daily record of severity of problems (DRSP) at baseline and after 8 weeks of treatment.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026